Form 4: Pfizer Executive Andrew Baum Reports Acquisition of Stock Appreciation Rights

Executive Vice President Andrew Baum reports the acquisition of stock appreciation rights (SARs) convertible to Pfizer common stock.

Summary

• On March 4, 2025, Andrew Baum, an Executive Vice President at Pfizer Inc., reported the acquisition of 206,569 stock appreciation rights (SARs).
• These SARs, priced at $25.75, will be settled in shares of Pfizer common stock on March 4, 2030, subject to certain vesting requirements.
• The transaction was reported on a Form 4 filing with the Securities and Exchange Commission.
• A power of attorney was executed on February 24, 2025, granting several individuals the authority to complete and sign SEC filings on Baum's behalf.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The acquisition of SARs by an executive is generally viewed as a mildly positive signal.

Positives

• The acquisition of SARs by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding Pfizer's overall performance, but the vesting of the SARs is contingent on future events.

Industry Context

Executive compensation in the pharmaceutical industry often includes stock-based awards like SARs to align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock appreciation rights are a common form of equity compensation used by large pharmaceutical companies like Johnson & Johnson, Merck, and AbbVie to incentivize executives.
• The vesting schedules and terms of these awards typically vary based on company performance and individual executive goals.

Stakeholder Impact

• The granting of SARs aligns the executive's interests with those of shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates